Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Erdafitinib in Advanced Solid Tumors With FGFR Alterations
CTR20200475Phase 2Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Mar 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of erdafitinib in Nonhematologic neoplasms, brain neoplasm, sponsored by Janssen Pharmaceutical. Started Mar 2020; status: completed.
02
Drugs
erdafitinib
03
Conditions
Nonhematologic neoplasmsbrain neoplasm
Beyond the preview
Go deeper on CTR20200475.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20200475.